CoLucid Pharmaceuticals, Inc.
CLCD
CLCD was delisted on the 28th of February, 2017.
22 hedge funds and large institutions have $34.1M invested in CoLucid Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
71% more capital inflows, than outflows
Capital inflows: $1.05M | Capital outflows: $614K
36% more ownership
Funds ownership: 0% → 36% (+36%)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
5% more funds holding
Funds holding: 21 → 22 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EverPoint Asset Management
Stamford,
Connecticut
|
+$866K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$100K |
| 3 |
Morgan Stanley
New York
|
+$46.9K |
| 4 |
SG Americas Securities
New York
|
+$28.1K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$4.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pentwater Capital Management
Naples,
Florida
|
-$220K |
| 2 |
UBS O'Connor
Chicago,
Illinois
|
-$199K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$124K |
| 4 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$44.9K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$17.5K |
CLCD Hedge Fund Activity: Q1 2016 in Review
22 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in CoLucid Pharmaceuticals, Inc. (CLCD) for Q1 2016, worth a combined $34.1M — down 25% from $45.4M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CLCD positions and 1 closed out — a net gain of 1 holder — while 7 added to existing stakes and 6 trimmed.
The largest buyer was EverPoint Asset Management, adding an estimated $866K. The largest seller was Pentwater Capital Management, exiting entirely with an estimated $220K sold.
- 22 institutional investors held CoLucid Pharmaceuticals, Inc. (CLCD) as of Q1 2016, up from 21 in Q4 2015.
- Funds reported $34.1M of CoLucid Pharmaceuticals, Inc. stock for Q1 2016, down 25% quarter-over-quarter.
- 2 funds opened new CoLucid Pharmaceuticals, Inc. positions in Q1 2016 and 1 closed out, a net change of +1 holder.
- The largest CoLucid Pharmaceuticals, Inc. buyer in Q1 2016 was EverPoint Asset Management, an estimated $866K added.
- The largest CoLucid Pharmaceuticals, Inc. seller in Q1 2016 was Pentwater Capital Management, an estimated $220K sold.
Based on aggregated 13F filings for Q1 2016.